| Kingsrose Mining Limited (KRM) ORDINARY FULLY PAID |
Materials |
$18 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Apr 2026 9:18AM |
$0.032 |
$0.024 |
fallen by
25%
|
|
KRM - Price-sensitive ASX Announcement
Full Release
Key Points
- Kingsrose Mining Limited reported its quarterly activities for the period ending 31 March 2026.
- The company focused on exploration and operations, particularly in the Råna Project, Norway, and the Penikat Project, Finland.
- A partnership with BHP for the Finnmark Exploration was highlighted.
- The company's sustainability and permitting activities were discussed.
- A review of cash flow, expenditure, and financial standing was provided.
- The report included a summary of mining tenements and areas of interest.
- Kingsrose holds several exploration licenses in Finnmark, Norway.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| First Au Limited (FAU) ORDINARY FULLY PAID |
Materials |
$24 |
Environmental & Scoping Level Technical Studies for Gimlet
|
30 Apr 2026 9:17AM |
$0.011 |
$0.007 |
fallen by
36.36%
|
|
FAU - Price-sensitive ASX Announcement
Full Release
Key Points
- FAU enters an agreement with Newcam Minerals for Gimlet Gold Project.
- Scoping studies include metallurgical and mining planning.
- Environmental baseline work will support future development.
- Estimated study costs of A$750,000 paid in FAU shares.
- Gimlet's resource is 1.58 Mt at 2.22 g/t Au for 112,900 ounces.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| iCetana Limited (ICE) ORDINARY FULLY PAID |
Information Technology |
$22 |
Proposed issue of securities - ICE
|
30 Apr 2026 9:17AM |
$0.035 |
$0.033 |
fallen by
5.71%
|
|
| iCetana Limited (ICE) ORDINARY FULLY PAID |
Information Technology |
$22 |
Proposed issue of securities - ICE
|
30 Apr 2026 9:17AM |
$0.035 |
$0.033 |
fallen by
5.71%
|
|
| iCetana Limited (ICE) ORDINARY FULLY PAID |
Information Technology |
$22 |
Investor presentation
|
30 Apr 2026 9:17AM |
$0.035 |
$0.033 |
fallen by
5.71%
|
|
ICE - Price-sensitive ASX Announcement
Full Release
Key Points
- Icetana's AI technology allows a single operator to manage over 1,000 cameras in real-time.
- The company is focusing on the Australian retail mall market with plans for scalable rollouts through partnerships.
- Icetana reports an annual recurring revenue (ARR) of $2.6 million with approximately 90% gross margin.
- The presentation highlights increasing crime rates that expose gaps in Australia's security infrastructure.
- Icetana's solution involves predictive security transitioning from detection and triage to prediction and automation.
- The company emphasizes the competitive advantage of being in AI surveillance for 15 years.
- Icetana operates with a private AI engine designed for modern security operations, dubbed the Antara Core.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| iCetana Limited (ICE) ORDINARY FULLY PAID |
Information Technology |
$22 |
icetana AI completes $4m placement
|
30 Apr 2026 9:17AM |
$0.035 |
$0.033 |
fallen by
5.71%
|
|
ICE - Price-sensitive ASX Announcement
Full Release
Key Points
- icetana AI completed a $4 million placement to institutional and sophisticated investors.
- The placement was oversubscribed, reflecting investor confidence.
- Proceeds will accelerate conversion of the sales pipeline into contracted ARR.
- The funds will also scale global deployments through partner channels.
- Recent momentum includes a ~$250k ARR order in Japan.
- The placement issued 125,000,000 new shares at $0.032 each.
- The placement was managed by Templar Corporate Pty Ltd.
- Lead Manager received 7,500,000 shares and 31,250,000 options, subject to approval.
- The funds will support global sales, product development, and working capital.
- icetana AI's technology is deployed across 70+ sites and 19,000+ cameras in 15+ countries.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Microba Life Sciences Limited (MAP) ORDINARY FULLY PAID |
Health Care |
$28 |
Q3 FY26 Quarterly Investor Presentation & Webinar
|
30 Apr 2026 9:17AM |
$0.070 |
$0.040 |
fallen by
42.86%
|
|
MAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Core testing revenues up 99% year-over-year.
- Test volumes increased by 58%.
- On track for over 24,000 FY26 core test volume.
- Regional break-even goals for Australia and UK.
- Expansion in clinical adoption in Australia and UK.
- Introduction of new product features and a clinical integration platform.
- Growth in the supplement segment focusing on Invivo branded products.
- Advancement in therapeutics through partnerships.
- Stable pricing and operational efficiencies assumed for financial forecasts.
- Focus on sufficient capital for expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Foundation Investment Company Limited (AFI) ORDINARY FULLY PAID |
Financials |
$8,514 |
Update - Notification of buy-back - AFI
|
30 Apr 2026 9:17AM |
$6.610 |
$6.890 |
risen by
4.24%
|
|
| Athena Resources Limited (AHN) ORDINARY FULLY PAID |
Materials |
$11 |
Trading Halt
|
30 Apr 2026 9:16AM |
$0.005 |
$0.004 |
fallen by
20%
|
|
AHN - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Athena Resources Limited (ASX: AHN).
- Pending announcement regarding a capital raising.
- Trading halt effective until 4 May 2026 or announcement release.
- Request authorized by the company's Board of Directors.
- No known reasons to deny the trading halt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bubs Australia Limited (BUB) ORDINARY FULLY PAID |
Consumer Staple |
$71 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Apr 2026 9:16AM |
$0.110 |
$0.079 |
fallen by
28.18%
|
|
BUB - Price-sensitive ASX Announcement
Full Release
Key Points
- Bubs Australia Limited reported a 10% increase in net revenue for Q3 FY26, totaling $25.5 million.
- Significant growth in the United States market with store distribution increasing by approximately 98%.
- The company maintained a liquidity position of $21.9 million, including $5.9 million in cash and $16.0 million in undrawn debt facilities.
- Challenges were noted due to geopolitical tensions, which impacted supply chains and logistics costs.
- Cash flows from operating activities showed a negative $6.3 million for Q3 due to increased inventory levels.
- Bubs continues to engage positively with the FDA as part of its regulatory efforts.
- The report emphasized the focus on expanding product range and supply chain capabilities to meet growing demand.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Haranga Resources Limited (HAR) ORDINARY FULLY PAID |
Materials |
$43 |
Trading Halt
|
30 Apr 2026 9:16AM |
$0.130 |
$0.096 |
fallen by
26.15%
|
|
HAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Haranga Resources Limited requested a trading halt on 30 April 2026.
- The trading halt was in anticipation of an announcement regarding exploration results from the Lincoln Gold Project.
- The halt will last until the release of the announcement or the commencement of normal trading on 4 May 2026.
- Haranga Resources Limited is not aware of any reason the trading halt should not be granted.
- The request was made in accordance with ASX Listing Rule 17.1.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Condor Energy Limited (CND) ORDINARY FULLY PAID |
Energy |
$12 |
Trading Halt
|
30 Apr 2026 9:15AM |
$0.021 |
$0.014 |
fallen by
33.33%
|
|
CND - Price-sensitive ASX Announcement
Full Release
Key Points
- Condor Energy Limited (ASX: CND) has requested a trading halt on its securities.
- The trading halt is pending the release of an announcement regarding a capital raising.
- The trading halt is effective as of 30 April 2026.
- Trading is expected to resume on 4 May 2026 or upon the announcement release, whichever is earlier.
- The request for the trading halt is in accordance with ASX Listing Rule 17.1.
- Condor Energy Limited is not aware of any reason why the trading halt should not be granted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rimfire Pacific Mining Limited (RIM) ORDINARY FULLY PAID |
Materials |
$31 |
March 2026 Quarterly Activities and Cashflow Report
|
30 Apr 2026 9:15AM |
$0.013 |
$0.011 |
fallen by
12%
|
|
RIM - Price-sensitive ASX Announcement
Full Release
Key Points
- Murga Scandium Deposit's Mineral Resource estimate increased by 300%.
- Rimfire exercised option to acquire 100% of Rabbit Trap Scandium Project.
- Rimfire's global scandium resource inventory now totals 10.6Kt Sc.
- Cash balance at 31 March 2026 was $1.03M.
- Net cash used in operating activities was $136,000 for the quarter.
- Resource upgrade positions Rimfire as a key player in the Fifield District.
- Rimfire plans further drilling and metallurgical test work in June 2026 Quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Artrya Limited (AYA) ORDINARY FULLY PAID |
Health Care |
$849 |
March Quarterly Activities Report and Appendix 4C
|
30 Apr 2026 9:15AM |
$4.120 |
$5.210 |
risen by
26.46%
|
|
AYA - Price-sensitive ASX Announcement
Full Release
Key Points
- Salix® platform fully integrated across Tanner Health hospitals.
- Northeast Georgia Health System and Cone Health preparing for Salix® integration.
- Salix® Coronary Flow module nearing FDA submission.
- SAPPHIRE Study contracting and ethics submissions underway.
- Net cash inflow of $0.06M for the quarter.
- Cash position at $76.6M.
- Included in the S&P/ASX All Ordinaries Index.
- Strengthened U.S. leadership and board appointments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Orthocell Limited (OCC) ORDINARY FULLY PAID |
Health Care |
$207 |
First Sales of Remplir Achieved in US$75m Canadian Market
|
30 Apr 2026 9:14AM |
$0.880 |
$0.760 |
fallen by
13.64%
|
|
OCC - Price-sensitive ASX Announcement
Full Release
Key Points
- First commercial sales of Remplir in Canada.
- Regulatory approval from Health Canada achieved in 2H CY25.
- Distributor-led model facilitates market entry.
- Remplir sales mark a milestone in global rollout.
- Significant national coverage established in Canada.
- Expansion plans include EU/UK market.
- Company well-funded with A$48 million in cash.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Delorean Corporation Limited (DEL) ORDINARY FULLY PAID |
Utilities |
$23 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Apr 2026 9:14AM |
$0.105 |
$0.091 |
fallen by
13.33%
|
|
DEL - Price-sensitive ASX Announcement
Full Release
Key Points
- Cash balance of $7.2 million as at 31 March 2026.
- Receipt of $0.8 million from customers in the quarter.
- SA1 Salisbury project achieved second ARENA milestone with $1.1 million grant.
- NSW1 Horsley Park facility secured $30.5 million in grants and reached Final Investment Decision.
- Net cash used in operating activities totaled $1.35 million for the quarter.
- Net cash used in investing activities was $6.6 million.
- Net cash from financing activities amounted to $10.3 million.
- Delorean focuses on bioenergy infrastructure development and operation.
- Strong policy momentum for renewable gas supports Delorean's market position.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Patrys Limited (PAB) ORDINARY FULLY PAID |
Health Care |
$26 |
Appendix 4C - Quarterly - 31 March 2026
|
30 Apr 2026 9:13AM |
$0.031 |
$0.039 |
risen by
25.81%
|
|
PAB - Price-sensitive ASX Announcement
Full Release
Key Points
- Patrys Limited completed the acquisition of Reliis Pty Ltd.
- The lead program RLS-2202 (injectable quetiapine) is advancing towards Phase 1A clinical trials.
- The company is working on its deoxymab platform and assessing strategic opportunities.
- Engineering batch manufacturing began at BioCina for clinical supply preparation.
- US regulatory engagement has started, preparing for FDA submissions.
- Patrys appointed Dr. Samantha South as CEO and added two Non-Executive Directors.
- The company completed a A$3.2 million Placement to support clinical and regulatory milestones.
- Cash balance at the end of the quarter was A$1.196 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dimerix Limited (DXB) ORDINARY FULLY PAID |
Health Care |
$114 |
Dimerix Quarterly Activities Report and Appendix 4C
|
30 Apr 2026 9:13AM |
$0.215 |
$0.190 |
fallen by
11.63%
|
|
DXB - Price-sensitive ASX Announcement
Full Release
Key Points
- Dimerix appoints Mike Tonroe as inaugural in-house CFO and company secretary.
- Dimerix is in late-stage discussions for non-dilutive funding up to US$50 million.
- The ACTION3 Phase 3 trial for FSGS has completed adult recruitment.
- The trial is statistically powered to demonstrate proteinuria reduction.
- Dimerix and partners decided to continue the trial to the final endpoint for better regulatory success.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Godolphin Resources Limited (GRL) ORDINARY FULLY PAID |
Materials |
$14 |
Proposed issue of securities - GRL
|
30 Apr 2026 9:13AM |
$0.023 |
$0.017 |
fallen by
26.09%
|
|
| Godolphin Resources Limited (GRL) ORDINARY FULLY PAID |
Materials |
$14 |
$2.5m Placement to Accelerate Lewis Ponds Project
|
30 Apr 2026 9:13AM |
$0.023 |
$0.017 |
fallen by
26.09%
|
|
GRL - Price-sensitive ASX Announcement
Full Release
Key Points
- A$2.5 million raised through placement.
- 147.1 million shares issued at $0.017 per share.
- Placement supported by new and existing investors.
- Funds directed to Lewis Ponds project development.
- 2,500m diamond drilling program planned.
- Focus on resource expansion and metallurgical testing.
- Lewis Ponds project shows strong economic potential.
- Taylor Collison Limited was Lead Manager.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Electro Optic Systems Holdings Limited (EOS) ORDINARY FULLY PAID |
Industrials |
$2,046 |
Quarterly Activity Report and Appendix 4C - March 2026 qtr
|
30 Apr 2026 9:12AM |
$9.530 |
$9.440 |
fallen by
0.94%
|
|
EOS - Price-sensitive ASX Announcement
Full Release
Key Points
- Contract backlog at $518 million as of 31 March 2026.
- Secured a $100 million two-year loan facility.
- Joint venture planned in the Middle East for R150 Remote Weapon System.
- Operating cash flow for the quarter was $9.5 million.
- Customer cash receipts totaled $72.6 million.
- Active market development and partnerships, including agreements with ROKETSAN and KNDS.
- Settlement of ASIC investigation with a $4 million penalty.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lotus Resources Limited (LOT) ORDINARY FULLY PAID |
Energy |
$180 |
Quarterly Activities and Cash Flow Reports - March 2026
|
30 Apr 2026 9:12AM |
$1.425 |
$0.660 |
fallen by
53.68%
|
|
LOT - Price-sensitive ASX Announcement
Full Release
Key Points
- Lotus Resources Limited operates the Kayelekera Uranium Mine in Malawi and the Letlhakane Uranium Project in Botswana.
- The company reported no Lost Time Injuries in the March 2026 quarter and focused on a strong safety culture.
- Lotus has upgraded infrastructure at Kayelekera, including a laboratory, and strengthened the site leadership team.
- Kayelekera achieved uranium product acceptance by the Orano conversion facility in France.
- The mining activities are progressing with mining now across three fronts.
- Production improvements are ongoing, but were impacted by reagent supply issues and plant maintenance.
- Cash flow from operating activities was negative, but financing activities provided a boost to cash reserves.
- Lotus completed a share placement and SPP raising a total of A$79M before costs.
- Lotus is pursuing inventory financing options in anticipation of the first shipment.
- The company holds 85% interest in Kayelekera and 100% in Letlhakane.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Microba Life Sciences Limited (MAP) ORDINARY FULLY PAID |
Health Care |
$28 |
Q3 FY26 Quarterly Activities Report & Appendix 4C
|
30 Apr 2026 9:12AM |
$0.070 |
$0.040 |
fallen by
42.86%
|
|
MAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Core testing revenue increased by 99% year-over-year.
- Microbiome Explorer tests sold in Australia reached 4,786, marking a 49% increase compared to the previous corresponding period.
- In the UK, Microbiome Explorer sales were up 232% year-over-year with 816 tests sold.
- The company signed 27 new enterprise-clinic accounts since November 2025.
- Cash receipts for Q3 FY26 were $3.98 million.
- Total revenue for Q3 FY26 was $3.36 million.
- Supplement business showed strong momentum with PHGG prebiotic fibre supplement volume up 161% year-over-year.
- Microba is engaged in confidential negotiations for a significant corporate transaction.
- Deferred revenue for the Microbiome Explorer reached $1.55 million at the end of March 2026, up 62% year-over-year.
- The MetaPanel test product demonstrated strong clinical validation, supporting its adoption.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fin Resources Limited (FIN) |
Materials |
$9 |
Quarterly Activities Report & Appendix 5B
|
30 Apr 2026 9:11AM |
$0.011 |
$0.006 |
fallen by
45.45%
|
|
FIN - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities Report & Appendix 5B cover period ending 31 March 2026.
- Exploration focus on Cabin Lake Gold Project with confirmed high-grade gold mineralisation.
- Financial position includes A$1.64 million cash and A$1.2 million from equity tranche.
- Total exploration expenditure of A$1.7 million and corporate costs of A$183K.
- Successful completion of A$3.75 million equity raising.
- Ongoing exploration supported by geophysics and drilling programs.
- Engagement with Tlic?ho Government for project support.
- Forward-looking statements outline strategic project plans.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ballymore Resources Limited (BMR) ORDINARY FULLY PAID |
Materials |
$28 |
Trading Halt
|
30 Apr 2026 9:11AM |
$0.145 |
$0.115 |
fallen by
20.69%
|
|
BMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Ballymore Resources Limited requested a trading halt.
- The trading halt is pending a material capital raising announcement.
- The halt will last until normal trading on 4 May 2026 or an earlier announcement.
- There is no known reason for the halt to be denied.
- The request was made in compliance with ASX Listing Rule 17.1.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
